Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellmid Announces That British Journal of Pharmacology Features Midkine

Published: Saturday, March 08, 2014
Last Updated: Saturday, March 08, 2014
Bookmark and Share
BJP features midkine in a special edition with 16 new publications.

Cellmid Limited advises that The British Journal of Pharmacology (BJP) has recently published a special edition dedicated to midkine (MK) including 16 research papers by various authors.

The BJP is the premier peer-reviewed publication of the British Pharmacological Society, and it is recognized as one of the most influential international journals covering all aspects of experimental pharmacology.

The BJP Midkine Issue contains invited reviews from pre-eminent MK researchers from around the world, with comprehensive up-to-date articles covering the gamut of MK biology. Publications examine the role of MK in diseases including various cancers, kidney diseases, cardiovascular disease, multiple sclerosis and neurodegenerative disorders. New understanding of MK signaling and receptors is also featured.

The full table of contents and the articles themselves can be viewed at
http://onlinelibrary.wiley.com/doi/10.1111/bph.2014.171.issue-4/issuetoc.

“Being featured in a high-impact, internationally regarded journal with a global audience is a strong validation of MK’s importance in health and disease”, said Cellmid CEO, Maria Halasz. “Cellmid recognized this potential early on, and it is pleasing to see the increasing and ever wider realization of MK’s potential utility as a disease target or as a therapeutic agent in its own right.”

“Having MK reviewed in this way is very helpful to Cellmid’s product development programs”, added Darren Jones, Head of Product Development. “Publications such as these provide strong supporting evidence to regulators, key opinion leaders and potential biotech and pharma partners. They provide a solid foundation upon which Cellmid can build its clinical programs and collaborations.”

Since its discovery in 1988, MK has been the subject of over 670 peer-review papers.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellmid Signs Midkine Diagnostic Agreement
Multiple cancer diagnostic products are expected to be developed.
Monday, February 11, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!